Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Reply to comments about “Aldosterone breakthrough”

Hypertension Research volume 46, pages 1351–1352 (2023)Cite this article

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Mogi M. Aldosterone breakthrough from a pharmacological perspective. Hypertens Res. 2022;45:967–75.

    Article  PubMed  Google Scholar 

  2. Lopez AG, Louiset E, Lefebvre H. Aldosterone breakthrough as a clue to the physiological importance of paracrine regulation of aldosterone secretion. Hypertens Res. 2022;45:1832–4.

    Article  CAS  PubMed  Google Scholar 

  3. Jose A. Aldosterone breakthrough from a pharmacological perspective. Hypertens Res. 2023;46. https://doi.org/10.1038/s41440-023-01204-2

  4. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension 2020;75:51–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, Ehime University, Graduate School of Medicine, Shitsukawa, Tohon, Ehime, 791-0295, Japan

    Masaki Mogi

Authors
  1. Masaki Mogi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaki Mogi.

Ethics declarations

Conflict of interest

The author declares no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mogi, M. Reply to comments about “Aldosterone breakthrough”. Hypertens Res 46, 1351–1352 (2023). https://doi.org/10.1038/s41440-023-01235-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41440-023-01235-9

Keywords

This article is cited by

Search

Advanced search

Quick links